Literature DB >> 24494066

Blood coagulation induced by Iranian saw-scaled viper (echis carinatus) venom: identification, purification and characterization of a prothrombin activator.

Mahdi Babaie1, Hossein Salmanizadeh1, Hossein Zolfagharian2.   

Abstract

OBJECTIVE(S): Echis carinatus is one of the venomous snakes in Iran. The venom of Iranian Echis carinatus is a rich source of protein with various factors affecting the plasma protein and blood coagulation factor. Some of these proteins exhibit types of enzymatic activities. However, other items are proteins with no enzymatic activity.
MATERIALS AND METHODS: In order to study the mechanism and effect of the venom on human plasma proteins, the present study has evaluated the effect of crude venom and all fractions. A procoagulant factor (prothrombin activator) was isolated from the venom of the Iranian snake Echis carinatus with a combination of gel filtration (Sephadex G-75), ion-exchange chromatography (DEAE- Sepharose) and reverse phase HPLC. Furthermore, proteolytic activity of the crude venom and all fractions on blood coagulation factors such as prothrombin time (PT) was studied.
RESULTS: In the present study, the PT test was reduced from 13.4 s to 8.6 s when human plasma was treated with crude venom (concentraion of venom was 1 mg/ml). The purified procoagulant factor revealed a single protein band in SDS polyacrylamide electrophoresis under reducing conditions and its molecular weight was estimated at about 65 kDa. A single-band protein showed fragment patterns similar to those generated by the group A prothrombin activators, which convert prothrombin into meizothrombin independent of the prothrombinase complex.
CONCLUSION: This study showed that the fraction which separated from Iranian snake Echis carinatus venom can be a prothrombin activators. It can be concluded that this fraction is a procoagulant factor.

Entities:  

Keywords:  Blood coagulation; Chromatography; Iranian Echis carinatus; Prothrombin time; Protrombin activator

Year:  2013        PMID: 24494066      PMCID: PMC3909625     

Source DB:  PubMed          Journal:  Iran J Basic Med Sci        ISSN: 2008-3866            Impact factor:   2.699


Introduction

Snake venom, a complex mixture principally composed of proteins and peptides, exhibits diverse biological activities that affect several vital systems (1). Echis carinatus (Saw scaled viper) is a venomous snake found in the desert regions of Iran. The venom of E. carinatus, a member of the Viperidae family, affects blood coagulation due to hemostatically active enzymes with procoagulant and anticoagulant activity (2, 3). The venom of E. carinatus affects the blood circulation. This venom is very toxic causing severe tissue and organ damage. The venom of E. carinatus is rich in proteins and peptides effective on the hemostatic system, i.e., its acts against some types of factors involving coagulation and fibrinolysis (4, 5). E. carinatus snake venom especially contains proteins affecting the transformation of the prothrombin into thrombin (6). Prothrombin is the protein which is broken in plasma by ecarin. In fact, this protein cleaves the bond in prothrombin and produces meizothrombin, which is converted into α-thrombin by autolysis (7). The conversion of the prothrombin into thrombin is one of the central reactions of blood coagulation (8, 9). The physiological activation of prothrombin to the serine proteinase α-thrombin is catalysed by prothrombinase complex consisting of the serine proteinase, factor Xa, cofactor Va and Ca2+. Membranes containing anionic phospholipids are essential for the optimal function of this enzyme complex (10, 11). However, the rate of activation is five orders of magnitude lower than the activation by prothrombinase complex (12), and the mechanism of cleavage proceeds through prethrombin-2 rather than through meizothrombin (13). The venom of Viperidae presents a high level of haemorrhagic, coagulant and proteolytic activities (14). Proteins effective on blood coagulation and existing in the snake venom are classified based on their ability to lengthen or shorten the clotting process into coagulation and anticoagulation proteins (15). The aim of the present investigation was to study the purification and characterization of porothrombin activator (procoagulant factor) from the Iranian E. carinatus venom and to evaluate the procoagulant activity on in vitro human plasma.

Materials and Methods

The lyophilized E. carinatus venom was obtained from the Department of Venomous Animals and Antivenom Production, Razi Vaccine and Serum Research Institute Karaj, Iran. Sephadex G-75, DEAE-Sepharose, and C18 columns were purchased from the Pharmacia company (Sweden). CaCl2 and PT kits were purchased from the Fisher Diagnostics (USA). Protein markers were obtained from BioRad (Hercules, USA). Other reagents and chemicals were of analytical grade from Fluka and Merck. Normal plasma from 20 healthy donors without any history of bleeding or thrombosis was collected from a private clinical laboratory. The citrated blood was centrifuged for 15 min at 3,000 rpm, to get clear plasma. Finally, the PT was estimated. The total protein of crude venom of E. carinatus, and its fractions were determined by Lowry method (16). Purification of the prothrombin activator was performed in three steps. Lyophilized crude venom of E. carinatus (50 mg) was dissolved in 4 ml of starting buffer (20 mM ammonium acetate, pH 6.8) and centrifuged at 3,000 rpm for 15 min, 4°C. The supernatant was filtered on a 0.45 microfilter to remove all insoluble materials. The supernatant was then applied into a Superdex G-75 column and eluted with the same buffer. (150 × 3 cm). Fractions were collected at 4°C and their absorbances were recorded at 280 nm. The fractions with proguaolant activity were pooled, lyophilized and dialyzed against 50 mM Tris-HCl, pH 8.2 buffers. The dialyzed sample was centrifuged at 3000 rpm to clear the precipitated proteins. For further purification, the supernatant was loaded into ion exchange column (DEAE-Sepharose) and equilibrated with 50 mM Tris-HCl buffer, pH 8.2 and eluted with a liner gradient of Nacl concentration from 0.0 to 0.5 mM. The fractions exhibiting proguaolant activity in the previous step were pooled and dialyzed overnight at 4°C and applied on HPLC column, C18 (H2O, 0.1% trifluoroacetic acid), and eluted with a concentration gradient of solvent B (acetonitrile, 0.1% trifluoroacetic acid) from 0 to 100%, at a flow rate of 0.3 ml/min during 55 min. The peaks were monitored at 280 nm (17). Electrophoresis on 12/5% polyacrylamide gel was performed according to the method of Laemmli (18). Samples of the crude venom and its fractions were lauded and the molecular weights of protein were determined under reduced conditions. For the PT test, 200 μl of the PT reagent was added to 100 μl of citrated plasma (incubated for 1 min at 37°C). The time from the plasma-reagent mixing to the clot formation was defined as the PT and clotting time was recorded (19). The PT test was performed for different concentrations of crude venom and its fractions. Normal plasma comprised mixed samples from 20 healthy donors. It was briefly incubated at 37°C and sample aliquots containing some concentration of coagulant fractions or subfraction (50 µg/ml) were added, mixed and shaken and PT was then recorded.

Results

The present study showed that the crude venom of E. carinatus can accelerate the blood coagulation pathway. Our results indicated that as the concentration of venom increases, the PT of plasma decreased (Table 1).
Table 1

PT value for different concentration of E. carinatus crude venom

Concentrate of venom (mg/ml)Average of PT (S) *Preamble
0.0121 (P < 0.001)Clot is tiny
0.112.25 (P < 0.005)increased clot size
18.6 (P < 0.001)Clot complete
Control13.4 (P < 0.005)Clot complete

*n = 8

Total protein of the venom = 48300 μg/ml.

Control = 100 μl of citrated plasma + 200 μl of the PT reagent + Normal saline (Instead of venom).

Test = 100 μl of citrated plasma + 200 μl of the PT reagent + different concentrate of venom.

According to the Table 1, when the concentrations of venom increased from 0.01 to 1 mg/ml, the clotting time of plasma reduced from 13.4 to 8.6 sec. PT value for different concentration of E. carinatus crude venom *n = 8 Total protein of the venom = 48300 μg/ml. Control = 100 μl of citrated plasma + 200 μl of the PT reagent + Normal saline (Instead of venom). Test = 100 μl of citrated plasma + 200 μl of the PT reagent + different concentrate of venom. Purification of crude venom of Echis carinatus by Sephadex G-75 PT value for fractions of IEc crude venom * n=4, normal PT=13.4, F1 (P < 0.05) and F2 (P < 0.01) PT: prothrombin time Purification of F1 by DEAE-Sepharose chromatography HPLC of F1B fraction obtained from DEAE-Sepharose chromatography PT value for sub-fractions of E. carinatus venom * n=4, F1B (P-Value < 0.05) PT: prothrombin time Prothrombin Time for fractions obtained from HPLC * n=4, F1B4 (P-Value < 0.05) PT: prothrombin time Summerized PT value and total protein (crude venom, F1, F1B, F1B4) PT: prothrombin time According to the Table 1, when the concentrations of venom increased from 0.01 to 1 mg/ml, the clotting time of plasma reduced from 13.4 to 8.6 sec. As it is shown in the Figure 1, the three fractions (F1 to F3) were obtained By Sephadex G-75. Prothrombin time value was estimated for all the fractions. Our observation showed that the PT value for F1 is less than other fractions and this fraction can be considered as a procoagulant factor (Table 2).
Figure 1

Purification of crude venom of Echis carinatus by Sephadex G-75

Table 2

PT value for fractions of IEc crude venom

FractionsPT *
F112.3 sec
F235.5 sec
F3More than 300 sec

* n=4, normal PT=13.4, F1 (P < 0.05) and F2 (P < 0.01)

PT: prothrombin time

Further purification was performed by ion exchange chromatography DEAE-Sepharose. In this step, eight fractions were separated from F1A to F1H (Figure 2), out of eight fractions, only F1B showed procoagulant activity (Table 3).
Figure 2

Purification of F1 by DEAE-Sepharose chromatography

Table 3

PT value for sub-fractions of E. carinatus venom

FractionsPT *
Fraction F1A14 sec
Fraction F1B8 sec
Fraction F1C70 sec
Fraction F1D52 sec
Fraction F1E90 sec
Fraction F1F56 sec
Fraction F1GMore than 300 sec
Fraction F1H95 sec

* n=4, F1B (P-Value < 0.05)

PT: prothrombin time

The F1B was pooled, dialyzed and applied to a C18 reversed-phase HPLC column. Our results revealed that five peaks from F1B1 to F1B5 were isolated (Figure 3) and out of five fractions, only F1B4 showed coagulant activity (Table 4).
Figure 3

HPLC of F1B fraction obtained from DEAE-Sepharose chromatography

Table 4

Prothrombin Time for fractions obtained from HPLC

FractionsAverage of PT *
Fraction F1B1More than 300 sec
Fraction F1B2More than 300 sec
Fraction F1B3More than 300 sec
Fraction F1B43 sec
Fraction F1B5More than 300 sec

* n=4, F1B4 (P-Value < 0.05) PT: prothrombin time

Our results summarized in the Table 5, which showed that the PT value significantly decreased in the F1B4 as compared with PT value of the crude venom.
Table 5

Summerized PT value and total protein (crude venom, F1, F1B, F1B4)

StepProtein
Venom48.3 mg/ml
F1387.77 µg/ml
F1B130 µg/ml
F1B426 µg/ml

PT: prothrombin time

SDS-PAGE pattern of crude venom and its fraction: A: Crude venom and its fractions; B: Subfractions of F1; C: Fraction of F1B4 Crude venom and all fractions were analyzed by SDS-PAGE. As it is shown in the SDS-PAGE pattern, the molecular weight of crude venom and all of the fractions were estimated (Figure 4A, 4B and 4C). The molecular weights from the snake venom ranged from 6.5 to 250 kDa and the molecular weight of procoagulant factor was approximately 56 kDa. According to the Figure 4C, a single band of F1B4 indicates the purity of this protein.
Figure 4

SDS-PAGE pattern of crude venom and its fraction: A: Crude venom and its fractions; B: Subfractions of F1; C: Fraction of F1B4

Discussion

This study has investigated the venom of Iranian E. carinatus which contains a strong procoagulant factor enabling to activate the prothrombin. The functional properties of the E. carinatus prothrombin activator are similar to ecarin, the first prothrombin activator which was recently discovered to be present in the venom from E. carinatus (20). The venoms of many E. species are able to convert prothrombin into thrombin, either directly or indirectly (21). Under in vitro conditions, this venom also displays coagulation properties and increases the blood coagulation cascade. Crude venom from the Iranian snake E. carinatus was selected and assayed with PT test. Our results indicated that the Iranian E. carinatus venom has a procogulant activity and is able to coagulate human plasma rapidly (Table 1), therefore it may be concluded that IEc venom contains procoagulant factors. The present study reports an efficient and simple procedure for purification and isolation of procoagulant factor from IEc venom. The fraction F1B4 was isolated from IEC venom by a combination of several methods. Our results revealed that three peaks from F1B1 to F1B5 were isolated. In addition, out of five fractions, only F1B4 showed coagulant activity (Table 4). The molecular weight of this purified fraction was approximately estimated to be 56 kDa (Figure 4C). Our observation showed that the molecular weight of F1B4 is similar to prothrombin activator enzymes which have been already reported (20). Therefore, this coagulant factor may belong to the intermediate-molecular-weight group of these factors. By performing the prothrombin Time test on human plasma, the blood coagulation time on fraction F1 showed the least coagulation time and fraction F3 displayed the highest coagulation time. The total protein of crude venom is 48.3 mg/ml and the PT value is 8.6 s but in the hyper purified fraction with reducing amount of total protein (26.0 µg/ml), the PT value (3 s) also significantly decreased. It may be suggested that with low amount of total protein the PT value decreases. Some procoagulant factors, along with its molecular weights, have been reported by Howes JM et al in addition to the effects of three novel metalloproteinases (weighting 56 kDa) from the venom of the West African saw-scaled viper, E. ocellatus on blood coagulation and platelets (22). Daisuke Yamada et al isolated and characterized the carinactivase, a novel prothrombin activator from E. carinatus Venom with 62 kDa (23). Mikarin is the first group of IA prothrombin activator identified in the venom of a viperidae snake. In the case of prothrombin activator, it exhibited prothrombin activation, which was similar to the other group IA prothrombin activators, such as ecarin from E. Carinatus (24), aharin from Agkistrodon halys pallas (25) and prothrombin activator from Bothrops atrox (26). Over the past 20 years, many metalloproteinase have been isolated from snake venom with a wide variety of biological activities, including hemorrhagic (27), fibrinogenolytic and antiplatelet effects (28), as well as activation of prothrombin and factor X (29).

Conclusion

Protein with coagulation activities was purified from the venom of E. carinatus. The venom of E. carinatus including the Iranian E. carinatus is one of the coagulation venoms whose function is a pseudothromboplastin action. However, under in vitro conditions, this venom will generate high coagulation which is due to activation of the prothrombin. It is suggested that, this venom containing procoagulant factors with molecular weight of about 56 kDa. It seems the fraction F1B4 isolated from IEc to be like ecarin which is already reported.
  27 in total

Review 1.  Procoagulant proteins from snake venoms.

Authors:  R M Kini; V S Rao; J S Joseph
Journal:  Haemostasis       Date:  2001 May-Dec

2.  AN ENZYME CASCADE IN THE BLOOD CLOTTING MECHANISM, AND ITS FUNCTION AS A BIOCHEMICAL AMPLIFIER.

Authors:  R G MACFARLANE
Journal:  Nature       Date:  1964-05-02       Impact factor: 49.962

3.  WATERFALL SEQUENCE FOR INTRINSIC BLOOD CLOTTING.

Authors:  E W DAVIE; O D RATNOFF
Journal:  Science       Date:  1964-09-18       Impact factor: 47.728

4.  In vitro effects of Echis carinatus venom on the human plasma proteome.

Authors:  Roberto Guerranti; Alessio Cortelazzo; Nnadozie S Hope-Onyekwere; Emiliano Furlani; Helena Cerutti; Michele Puglia; Luca Bini; Roberto Leoncini
Journal:  Proteomics       Date:  2010-10       Impact factor: 3.984

Review 5.  Meizothrombin, a major product of factor Xa-catalyzed prothrombin activation.

Authors:  J Rosing; G Tans
Journal:  Thromb Haemost       Date:  1988-12-22       Impact factor: 5.249

6.  Effects of Pallas' viper (Agkistrodon halys pallas) venom on blood coagulation and characterization of a prothrombin activator.

Authors:  Y Zhang; W H Lee; R Gao; Y L Xiong; W Y Wang; S W Zhu
Journal:  Toxicon       Date:  1998-01       Impact factor: 3.033

7.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 8.  The coagulation explosion.

Authors:  K G Mann
Journal:  Ann N Y Acad Sci       Date:  1994-04-18       Impact factor: 5.691

9.  Coagulation factor X activating enzyme from Russell's viper venom (RVV-X). A novel metalloproteinase with disintegrin (platelet aggregation inhibitor)-like and C-type lectin-like domains.

Authors:  H Takeya; S Nishida; T Miyata; S Kawada; Y Saisaka; T Morita; S Iwanaga
Journal:  J Biol Chem       Date:  1992-07-15       Impact factor: 5.157

10.  Measurement of prothrombin time (PT) and activated partial thromboplastin time (APTT) on canine citrated plasma samples following different storage conditions.

Authors:  F Rizzo; K Papasouliotis; E Crawford; S Dodkin; S Cue
Journal:  Res Vet Sci       Date:  2007-11-12       Impact factor: 2.534

View more
  1 in total

1.  Purification of Therapeutic Serums of Snake Anti-Venom with Caprylic Acid.

Authors:  Nilofar Norouznejad; Hossein Zolfagharian; Mahdi Babaie; Maryam Ghobeh
Journal:  J Pharmacopuncture       Date:  2022-06-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.